Categories: News

STARMED Unveils New Brand Identity to Drive Global Multi-Modality Strategy

SEOUL, South Korea, Jan. 8, 2026 /PRNewswire/ — STARMED, a pioneer in innovative minimally invasive treatment solutions, has announced a comprehensive rebranding. Now in its seventeenth year of operation, the company is formally transitioning from a Radiofrequency Ablation (RFA) specialist into a global multi-modality medical technology platform.

- Advertisement -

Established in 2009, STARMED pioneered the first thyroid-dedicated RFA electrode, effectively creating a clinical field that did not previously exist. This technology has since been adopted into various international clinical guidelines and continues to maintain the leading global market share today. Building on this heritage, STARMED has expanded its portfolio to address diverse clinical needs in liver, uterine, and vascular care, introducing various products such as the proprietary multi-electrode Octopus system. The current rebranding signals a strategic commitment to expand beyond RFA by integrating diverse energy sources, including Microwave Ablation (MWA) and Irreversible Electroporation (IRE), into a unified therapeutic offering.

- Advertisement -

“With the global thermal ablation market projected to reach $2 billion by 2033, this rebranding is a pivotal step for our next stage of growth,” said CEO Henry Shin.

- Advertisement -

The newly unveiled Corporate Identity reflects both STARMED’s heritage and its future vision. The symbol represents technical precision by visualising the initial ‘S’ alongside the silhouette of an electrode tip. This reflects a dedication to minimising patient pain and providing care throughout the recovery process. The wordmark employs a sophisticated, futuristic typeface to reinforce trust within the global healthcare arena.

- Advertisement -

Supported by strong financial foundations, STARMED plans to capitalise on a market growing at 10.5% annually. The company remains committed to establishing minimally invasive treatments as the global ‘Standard of Care’ through enhanced clinical partnerships.

- Advertisement -

About STARMED

- Advertisement -

STARMED is a medical device specialist founded in 2009. With more than 660 clinical research evidence, the company provides world-class thermal ablation solutions to over 70 countries and continues to advance minimally invasive treatment as the clinical standard.

- Advertisement -

Photo – https://mma.prnewswire.com/media/2857156/STARMED_800px.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/starmed-unveils-new-brand-identity-to-drive-global-multi-modality-strategy-302655927.html

- Advertisement -

Recent Posts

Over 500 Leaders from Across More Than 50 Countries and Territories Attend 56th Annual World Trade Centers Association Global Business Forum in Philadelphia

Flagship WTCA event delivers high-impact sector insights and global business connections across industries NEW YORK,…

38 minutes ago

EquiLend Acquires Finadium, Expanding Presence in Securities Finance Research & Consulting

Finadium to continue operating independently as a subsidiary of EquiLendNEW YORK, May 12, 2026 /PRNewswire/…

38 minutes ago

MEXC Commits to $500M Guardian Fund Expansion, Acquires 1,000 BTC to Strengthen User Protection

VICTORIA, Seychelles, May 12, 2026 /PRNewswire/ -- MEXC, a pioneer in 0-fee digital asset trading,…

38 minutes ago

Maveric Systems announces strategic brand positioning focused on Engineering Trust in AI-First Banking

CHENNAI, India and DALLAS, May 12, 2026 /PRNewswire/ -- Maveric Systems, a banking-exclusive technology specialist,…

38 minutes ago

NYSE Content Update: Disney CEO Josh D’Amaro Rings Bell Ahead of Upfront Event

NYSE issues a pre-market daily advisory direct from the trading floor.NEW YORK, May 12, 2026…

3 hours ago

Halia Therapeutics to Present Final Phase 2 Ofirnoflast Data in Lower-Risk MDS at EHA2026 and Announces Appointment of Han Myint, MD, FACP, as Chief Medical Officer

European Hematology Association (EHA) oral presentation to report 67% hematological improvement, durable transfusion independence, and…

3 hours ago